Advertisement

L-threo-DOPS—implications for pathophysiology of parkinsonian symptoms chronically treated with L-DOPA

  • T. Kondo
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

During the course of the disease, several L-DOPA-unresponsive symptoms in parkinsonism become manifest. These symptoms, such as frozen gait, disturbance of postural adjustment and bradyphrenia, may be attributed to the abnormality of the nondopaminergic system in the brain.

L-threo-DOPS, a synthesized amino acid, is converted to norepinephrine (NE) by enzymic decarboxylation. Basic and clinical data indicate bifold actions of the substance. The substance permeates into the brain and acts as a precursor of NE not only in peripheral tissues but also in the brain, and enhances release of amines from respective nerve terminals.

The results of clinical investigations indicate that the action of the substance distributes from the reflex mechanism in the spinal cord to mental functions in the brain. Although the underlying mechanism of L-DOPA-resistant symptoms may not be simple, the effect of the substance on frozen gait of Parkinson’s disease in advanced stages suggests the importance of the role of the NE system in the disease.

Keywords

Parkinsonian Patient Spinal Trigeminal Nucleus Parkinsonian Brain Delay Reaction Time Enzymic Decarboxylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Araki H, Fujiwara H, Tanaka C (1981) Age-related changes in the chronotropic effect and the enzymic decarboxylation of L-threo-3,4-dihydroxyphenylserine in the rat heart. J Pharm Pharmacol 33: 778–782PubMedCrossRefGoogle Scholar
  2. Barbeau A (1974) The clinical physiology of side effects in long-term L-DOPA therapy. In: McDowell F H, Barbeau A (eds) Advances in neurology 5. Raven Press, New York, pp 347–365Google Scholar
  3. Bartholini G, Constantidinis J, Puig M, Tissot R, Pletscher A (1975) The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther 193: 523–532PubMedGoogle Scholar
  4. Bartholini G, Constantinidis J, Tissot R, Pletscher A (1971) Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase. Biochem Pharmacol 20: 1243–1247PubMedCrossRefGoogle Scholar
  5. Bernheimer H, Birkmayer W, Hornykiewicz O (1963) Zur Biochemie des Parkinson — Syndroms des Menschen—Einfluß der Monoaminoxydase-Hemmer-Therapie auf die Konzentration des Dopamins, Noradrenalins und 5-Hydroxytryptamins im Gehirn. Klin Wschr 41: 465–469CrossRefGoogle Scholar
  6. Birkmayer W, Danielzyk W, Neumayer E, et al. (1975) Dopaminergic supersensitivity in parkinsonism. Adv Neurol 9: 121–129PubMedGoogle Scholar
  7. Blaschko H, Chrusciel TL (I960) The decarboxylation of amino acids related to tyrosine and their awakening action in reserpine-treated mice. J Physiol 151: 272–284Google Scholar
  8. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology 37: 1539–1542PubMedGoogle Scholar
  9. Brannan T, Bhardwaj A, Yahr MD (1990) L-threodops increase extracellular norepinephrine levels in the brain: an in vivo study. Neurology 40: 1134–1135PubMedGoogle Scholar
  10. Cash R, Dennis T, L’Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37: 42–46PubMedGoogle Scholar
  11. Edwards DJ, Rizk M (1981) Effects of amino acid precursors on catecholamine synthesis in the brain. Prog Neuropsychopharmacol 5: 569–572PubMedCrossRefGoogle Scholar
  12. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3- Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38: 1236–1239PubMedCrossRefGoogle Scholar
  13. Gibson CJ (1988) Increase in norepinephrine turnover after tyrosine or DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS). Life Sci 42: 95–102PubMedCrossRefGoogle Scholar
  14. Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in parkinsonism. J Neurol Neurosurg Psychiatry 16: 213–226PubMedCrossRefGoogle Scholar
  15. Hirose A, Sasa M, Ohno Y, Takaori S (1988) Inhibitory effects of L-threo-DOPS, an L- noradrenaline precursor, on locus coeruleus-originating neurons in the caudate nucleus. Jpn J Pharmacol 48: 435–440PubMedCrossRefGoogle Scholar
  16. Hornykiewicz O (1973) Dopamine in the basal ganglia—its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull 29: 172–178PubMedGoogle Scholar
  17. Imai H (1980) Syndrome of pure akinesia or freezing phenomenon without rigidity and tremor and with no effect by L-DOPA therapy. Adv Neurol Sci 24: 838–848Google Scholar
  18. Inoue Y, Hoshino E, Sakamoto I, Yamashita Y, Ueda K, Hamazoe K, Fukuma E, Hazama H (1989) The effect of L-threo-3,4-dihydroxyphenylserine ( L-threo-DOPS) on sleep apnea syndrome. Jpn J Neuropsychopharmacol 11: 841–850Google Scholar
  19. Javoy-Agid F, Ruberg M, Pique L, Bertagna X, Taquet H, Studier JM, Cesselin F, Epilbaum J, Agid Y (1984) Biochemistry of the hypothalamus in Parkinson’s disease. Neurology 34: 672–675PubMedGoogle Scholar
  20. Jenner P, Sheehy M, Marsden CD (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine functions for the treatment of Parkinson’s disease. Br J Clin Pharmacol 15: 277s–289sPubMedGoogle Scholar
  21. Kato T, Katsuyama M, Karai N, Nakamura M, Katsube J (1987a) Studies on the central action of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in FLA-63-treated mice. Pharmacol Biochem Behav 26: 407–411PubMedCrossRefGoogle Scholar
  22. Kato T, Karai N, Katsuyama M, Nakamura M, Katsube J (1987b) Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain: comparison with that of L-DOPA. Biochem Pharmacol 36: 3051–3057PubMedCrossRefGoogle Scholar
  23. Kish SJ, Shannak KS, Rajput AH, Gilbert JJ, Hornykiewicz O (1984) Cerebellar norepinephrine in patients with Parkinson’s disease and control subjects. Arch Neurol 41: 612–614PubMedCrossRefGoogle Scholar
  24. Komiya T, Narabayashi H, Kondo T (1988) The effectivity of L-threo-3,4-dihydroxy- phenylserine ( L-threo-DOPS) to the hypersomnia and subcortical dementia caused by bilateral medial thalamic and midbrain infarcts. Clin Neurol 28: 268–271Google Scholar
  25. Kondo T (1984) DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS) treatment on the patients with Parkinson’s disease or pure akinesia. Clin Neurol 24: 280–288Google Scholar
  26. Mayeux R, Stern Y, Sano M, Cote L, Williams JBW (1987) Clinical and biochemical correlates of bradyphrenia in Parkinson’s disease. Neurology 37: 1130–1134PubMedGoogle Scholar
  27. Nagasaki H, Kosaka K, Nakamura R (1981) Disturbance of rhythm formation in patients with hemispheric lesion. Tohoku J Exp Med 135: 231–236PubMedCrossRefGoogle Scholar
  28. Nagatsu T, Yamaguchi T, Rahman MK, Trocewicz J, Oka K, Nagatsu I, Narabayashi H, Kondo T, Iizuka R (1984) Catecholamine-related enzymes and the biopterin cofactor in Parkinson’s disease and related extrapyramidal diseases. Adv Neurol 40: 467–473PubMedGoogle Scholar
  29. Nakajima Y, Kagamihara Y, Nagaoka M, Tanaka R (1987) The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson’s disease. Neurosci Res 5: 16–27PubMedCrossRefGoogle Scholar
  30. Nakamura R, Nagasaki H, Narabayashi H (1978) Arrhythmokinesia in parkinsonism. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 258–268Google Scholar
  31. Nakamura M, Kato T, Katsuyama M, Karai N, Kumasaka M, Shohno F (1987) Penetration of L-threo-DOPS, a precursor of norepinephrine, into the brain in various experimental animals. Jpn Pharmacol Ther 15 [Suppl 2]: 119–125Google Scholar
  32. Nakamura J, Kohgasa H, Hashimoto M, Furatsu M, Mitsune K, Horikawa Y, Inanaga K (1987) The effect of L-threo-DOPS on human CNS. Jpn Pharmacol Ther 15 [Suppl 2]: 153–160Google Scholar
  33. Naoi M, Nagatsu T (1986) Inhibition of monoamine oxidase by 3,4-dihydroxyphenyIserine. J Neurochem 47: 604–607PubMedCrossRefGoogle Scholar
  34. Naoi M, Nagatsu T (1987) Uptake of L-threo-dihydroxyphenylserine into human brain synaptosomes. J Neural Transm 70: 51–61PubMedCrossRefGoogle Scholar
  35. Narabayashi H, Nakanishi T, Yosida M, Yanagizawa N, Mizuno Y, Kanazawa I, Kondo T (1987) Therapeutic effects of L-DOPS in Parkinson’s disease — double-blind, comparative study against placebo as control in patients with the long-term levodopa therapy. Clin Eval 15: 423–457Google Scholar
  36. Narabayashi H, Kondo T (1987) Results of a double-blind study of L-threo-DOPS in Parkinsonism. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinson’s disease. Macmillan Healthcare information, Florham Park New Jersey, pp 279–291Google Scholar
  37. Narabayashi H, Imai H, Yokochi M, Hirayama K, Nakamura R (1976) Cases of pure akinesia without rigidity and tremor and with no effect by L-DOPA therapy. In: Birkmayer W, Hornykiewitz O (eds) Advances in parkinsonism. Roche, Basel, pp 335–342Google Scholar
  38. Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T (1981) L-threo-3,4- dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad 57 (Ser B): 351–354CrossRefGoogle Scholar
  39. Narabayashi H (1984) Akinesia in parkinsonism—clinical and pharmacological analysis of parkinsonian symptoms. Bull Acad Med Bel 139: 309–320Google Scholar
  40. Nishi K, Kondo T, Narabayashi H (1987) A mouse model of N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction. Brain and Nerve 39: 663–672PubMedGoogle Scholar
  41. Nishino K, Fujii Y, Kondo M, Shuntoh H, Fujiwara H, Tanaka C (1987) Effects of L- threo-3,4-dihydroxyphenylserine on efflux of monoamines and acetylcholine in guinea pig brain. J Pharmacol Exp Ther 242: 621–628PubMedGoogle Scholar
  42. Ogawa N, Kuroda H, Yamamoto M, Nukina I, Ota Z (1984) Improvement in freezing phenomenon of Parkinson’s disease after DL-threo-3,4-dihydroxyphenylserine. Acta Med Okayama 38: 301–304PubMedGoogle Scholar
  43. Ohtsuka M, Shimizu N, Dohbutsu M, Saitoh T, Kaneko J, Jyoshita Y, Mizuno Y, Yoshida M (1988) L-threo-3,4-dihydroxyphenylserine treatment for dementia of various etiologies. Neurol Ther 6: 355–360Google Scholar
  44. Parent A (1990) Extrinsic connections of the basal ganglia. TINS 13: 254–258PubMedGoogle Scholar
  45. Pillon B, Dubois B, Cusimano G, Bonnet A-M, Lhermitte F, Agid Y (1989) Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 52: 201–206PubMedCrossRefGoogle Scholar
  46. Pycock CJ, Donaldson I, MacG, Marsden CD (1975) Circling behaviour produced by unilateral lesions in the region of the locus coeruleus in rats. Brain Res 97: 317–329Google Scholar
  47. Reches A, Jackson-Lewis V, Fahn S (1985) DL-threo-DOPS as a precursor of noradrenaline. Arch Pharmacol 331: 202–208CrossRefGoogle Scholar
  48. Rinne UK, Sonninen V (1973) Brain catecholamines and their metabolites in parkinsonian patients. Arch Neurol 28: 107–110PubMedCrossRefGoogle Scholar
  49. Sasa M, Ohno Y, Nabatame H, Yoshimura N, Takaori S (1987) Effects of L-threo- DOPS, an L-noradrenaline precursor, on locus coeruleus-originating neurons in spinal trigeminal nucleus. Brain Res 420: 157–161PubMedCrossRefGoogle Scholar
  50. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 275: 321–328PubMedCrossRefGoogle Scholar
  51. Scatton B, Dennis T, L’Heureux R, Monfort JC, Duyckaerts C, Javoy-Agid F (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumber spinal cord of parkinsonian patients. Brain Res 380: 181–185PubMedCrossRefGoogle Scholar
  52. Stern Y, Mayeux R, Cote L (1984) Reaction time and vigilance in Parkinson’s disease. Possible role of altered norepinephrine metabolism. Arch Neurol 41: 1086–1089Google Scholar
  53. Semba J, Takahashi R (1985) The effects of L-threo-3,4-dihydroxyphenylserine on norepinephrine metabolism in rat brain. Psychiatr Res 15: 319–326CrossRefGoogle Scholar
  54. Suzuki T, Sakoda S, Ueji M, Kishimoto S (1985) Mass spectrometric measurements of norepinephrine synthesis in man from infusion of isotope-labelled L-threo-3,4- dihydroxyphenylserine. Life Sci 36: 435–442PubMedCrossRefGoogle Scholar
  55. Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H (1984) Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology 34: 1446–50PubMedGoogle Scholar
  56. Svenson TH (1969) On the significance of control noradrenalin for motor activity. Experiments with new dopamine-B-hydroxylase inhibitor. Eur J Pharmacol 7: 278–282CrossRefGoogle Scholar
  57. Takubo H, Kondo T (1988) Effects of L-threo-DOPS on monoamine metabolites and cyclic AMP in human cerebrospinal fluid — the evaluation of the mechanism for freezing phenomenon and akinesia. Jpn J Neuropsychopharmacol 10: 159–168Google Scholar
  58. Teelken AW, Berg GA van den, Muskiet FAJ, Staal-Schreinemachers AL, Wolthers BG, Lakke JPWF (1989) Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson’s disease. J Neural Transm 1: 177–188CrossRefGoogle Scholar
  59. Teramoto H, Yokochi M, Kujirai T, Aida K (1987) Clinical evaluation of L-thero-DOPS in parkinsonism with special reference to neuropsychiatrie study of 8 cases. Jpn J Clin Psychiat 16: 765–774Google Scholar
  60. Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y (1990) Effect of a synthetic norepinephrine precursor, L-threo-3,4-dihydroxyphenylserine of the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett 166: 194–197CrossRefGoogle Scholar
  61. Ueno E (1989) Clinical and physiological study of apraxia of gait and frozen gait. Clin Neurol 29: 275–283Google Scholar
  62. Yamamoto M, Ogawa N, Ujike H (1986) Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydro- xyphenylglycol. Concentration in patients with Parkinson’s disease. J Neurol Sci 73: 39–44Google Scholar
  63. Yamazaki M, Ikeda Y, Ishikawa M, Inagaki C, Tanaka C (1976) Inhibition of harmaline tremor induced by L-threo-3,4-dihydroxyphenylserine, a norepinephrine precursor. Folia Pharmacol Japon 72: 363–369CrossRefGoogle Scholar
  64. Yanagisawa N (1985) Disorders of voluntary movements in Parkinson’s disease. Jpn J Neuropsychopharmacol 7: 817–825Google Scholar
  65. Yokochi F, Nakamura R, Narabayashi H (1986) Basal ganglia and arousal — reaction time study in parkinsonian patients. Adv Neurol Sci 30: 841–846Google Scholar
  66. Yokota J, Ito K, Imai H, Narabayashi H (1990) The effect of L-threo-DOPS on P-300 in parkinsonism. Clin Neurol 30: 499–504Google Scholar
  67. Yoshida M, Nakanishi T (1988) Inhibitory effects of L-threo-DOPS on electroshock seijure in mice. Brain and Nerve 41: 567–573Google Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • T. Kondo
    • 1
  1. 1.Department of NeurologyJuntendo University School of MedicineBunkyo-ku, Tokyo 113Japan

Personalised recommendations